Table 3.
Association of apolipoprotein A-IV with incident cancer during the prospective follow-up in patients without a history of cancer at the baseline investigation (4424 out of 5039 patients) a
| HR | 95% CI | p-value | ||
|---|---|---|---|---|
| Calculations for median of apoA-IV concentrationsb | ||||
| Model 1: 368 cases (174 above and 194 below median)c | 0.73 | 0.58–0.91 | 0.006 | |
| Model 2: 362 cases (171 above and 191 below median)c | 0.72 | 0.57–0.90 | 0.004 | |
| Calculations per quartile of ApoA-IV concentrations | ||||
| Model 1 | Quartile 1 (90 cases)c | 1.00 | ||
| Quartile 2 (104 cases)c | 1.00 | 0.75–1.33 | 0.98 | |
| Quartile 3 (85 cases)c | 0.73 | 0.54–0.99 | 0.04 | |
| Quartile 4 (89 cases)c | 0.74 | 0.53–1.02 | 0.07 | |
| Model 2 | Quartile 1 (88 cases)c | 1.00 | ||
| Quartile 2 (103 cases)c | 1.02 | 0.76–1.36 | 0.91 | |
| Quartile 3 (83 cases)c | 0.72 | 0.53–0.98 | 0.04 | |
| Quartile 4 (88 cases)c | 0.73 | 0.53–1.02 | 0.07 | |
Model 1: adjusted for age, sex, ln-urine albumin-creatinine ratio and eGFRcystatin-C
Model 2: as model 1 plus statin use, smoking, BMI, diabetes
Abbreviations: HR hazard ratio, CI confidence interval
aPatients with a history of cancer at the time of enrollment were not considered in this analysis
bReference category includes apoA-IV values below median. The median apoA-IV concentration is 27.6 mg/dL (referring to the total group of 5039 patients)
c“Cases” refers to the number of patients with incident cancer events. Differences in number of cases between model 1 and 2 are explained by patients with few missing covariates for model 2